268 related articles for article (PubMed ID: 33548635)
21. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
Morsy A; Trippier PC
J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
[TBL] [Abstract][Full Text] [Related]
22. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
Suzuki N; Hatta T; Ito M; Kusakabe KI
Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
[TBL] [Abstract][Full Text] [Related]
23. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment.
Gazova Z; Soukup O; Sepsova V; Siposova K; Drtinova L; Jost P; Spilovska K; Korabecny J; Nepovimova E; Fedunova D; Horak M; Kaniakova M; Wang ZJ; Hamouda AK; Kuca K
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):607-619. PubMed ID: 27865910
[TBL] [Abstract][Full Text] [Related]
24. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
25. Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research.
Yang H; Zeng F; Luo Y; Zheng C; Ran C; Yang J
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745002
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's disease: from pathogenesis to disease-modifying approaches.
Galimberti D; Scarpini E
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):163-74. PubMed ID: 21222635
[TBL] [Abstract][Full Text] [Related]
27. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
28. Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.
Das S; Basu S
Curr Top Med Chem; 2017; 17(27):3017-3061. PubMed ID: 28685694
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
30. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.
Mezeiova E; Korabecny J; Sepsova V; Hrabinova M; Jost P; Muckova L; Kucera T; Dolezal R; Misik J; Spilovska K; Pham NL; Pokrievkova L; Roh J; Jun D; Soukup O; Kaping D; Kuca K
Molecules; 2017 Jul; 22(8):. PubMed ID: 28788095
[TBL] [Abstract][Full Text] [Related]
31. Synergistic Effect of Amyloid-β and Tau Disrupts Neural Circuits.
Tripathi T; Kalita P
ACS Chem Neurosci; 2019 Mar; 10(3):1129-1130. PubMed ID: 30702852
[TBL] [Abstract][Full Text] [Related]
32. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
34. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.
García-Font N; Hayour H; Belfaitah A; Pedraz J; Moraleda I; Iriepa I; Bouraiou A; Chioua M; Marco-Contelles J; Oset-Gasque MJ
Eur J Med Chem; 2016 Aug; 118():178-92. PubMed ID: 27128182
[TBL] [Abstract][Full Text] [Related]
35. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.
Hedberg MM; Clos MV; Ratia M; Gonzalez D; Lithner CU; Camps P; Muñoz-Torrero D; Badia A; Giménez-Llort L; Nordberg A
Neurodegener Dis; 2010; 7(6):379-88. PubMed ID: 20689242
[TBL] [Abstract][Full Text] [Related]
36. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease: emerging trends in small molecule therapies.
Mohamed T; Rao PP
Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
[TBL] [Abstract][Full Text] [Related]
38. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
Jouanne M; Rault S; Voisin-Chiret AS
Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
[TBL] [Abstract][Full Text] [Related]
39. Thiophene-Based Dual Modulators of Aβ and Tau Aggregation.
Ramesh M; Acharya A; Murugan NA; Ila H; Govindaraju T
Chembiochem; 2021 Dec; 22(23):3348-3357. PubMed ID: 34546619
[TBL] [Abstract][Full Text] [Related]
40. In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer's Disease Treatment.
Job N; Thimmakondu VS; Thirumoorthy K
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
